PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Rheumatology Department, Hospital Universitario de la Princesa, Madrid, Spain. mariadelrosario.garcia@salud.madrid.org.\', \'Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Madrid, Spain. mariadelrosario.garcia@salud.madrid.org.\', \'Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain. mariadelrosario.garcia@salud.madrid.org.\', \'Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Madrid, Spain.\', \'Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain.\', \'Clinical Pharmacology Department, Unidad de Investigación Clínica y Ensayos Clínicos (UICEC), Hospital Universitario de la Princesa, Plataforma SCReN (Spanish Clinical Research Network), Madrid, Spain.\', \'Rheumatology Department, Hospital Universitario de la Princesa, Madrid, Spain.\', \'Medical Affairs Department, Immunology Area, Sanofi Spain, Madrid, Spain.\', \'Division of Infectious Diseases, Internal Medicine Department, Hospital Universitario de la Princesa, Madrid, Spain.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-020-04588-5
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 32907638
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all